« Back
Home /
WHI-P97

WHI-P97

Item no.	HY-11067-2mg
Manufacturer	MedChem Express
CASRN	211555-05-4
Amount	2 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 2 mg 50 mg 5 mg
Category	Metabolism Cholesterol & Lipid Metabolism Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.70
Citations	[1]R Malaviya, et al. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther. 2000 Dec;295(3):912-26.
Smiles	BrC1=CC(NC2=NC=NC3=CC(OC)=C(OC)C=C32)=CC(Br)=C1O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	211555-05-4
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	JAK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	455.10
Product Description	WHI-P97 is a potent and selective JAK-3 inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo[1].
Manufacturer - Research Area	Inflammation/Immunology
Solubility	DMSO: 3.33 mg/mL (ultrasonic; warming; heat to 80°C)
Manufacturer - Pathway	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Isoform	JAK3
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-11067-2mg-safety-datasheet.pdf